Leaders in Fertility Research

Reproductive Medicine Associates (RMA) has been a pioneer in fertility science since its inception in 1999, with an unwavering commitment to improving patient outcomes.

rma research

Research & Innovation

Over the years RMA has evolved to become one of the most trusted authorities on all aspects of infertility, including research, education and patient care. This unparalleled emphasis on research and innovation has made possible quantum leap advancements in the practice of In Vitro Fertilization (IVF) that have given rise to a new standard of care for the industry and a new benchmark of success for patients.

Raising the Bar

Today, due to advancements encouraging Single Embryo Transfer (SET), IVF with RMA means a drastic reduction in multiple births resulting in a lower risk for mothers and babies. RMA’s singleton babies are now born with the same weight and term delivery rates as those conceived naturally.

steps of ivf
infertile couple

Improving Outcomes

How has RMA reduced the burden of care so quickly? By investing tens of millions of dollars into studying one question: how can IVF lead to one healthy baby?

The answer required getting several steps exactly right, and each clinical trial done at RMA inched doctors closer to finding the answer. Still, everyday doctors at RMA are working to further advance the field, finding answers to new questions that can improve outcomes and help couples complete their families safely and in the shortest time possible.

With a state-of-the-art laboratory, embryologists, scientists, and doctors as passionate as they are skilled, and a tireless focus on discovery, RMA is a worldwide leader in turning ideas into science, science into success, and success into families.

Research Oriented

RMA’s research has spanned the field of assisted reproduction and sought to make new discoveries in the areas of diminished ovarian reserve, endometriosis, Polycystic Ovary Syndrome (PCOS), male fertility, egg freezing, embryo biopsy, and testing, mosaicism, the microbiome, fibroids, stem cell rejuvenation, extended embryo culture, and dozens of more topics.

RMA’s April 2017 merger with IVI, Europe’s biggest IVF provider, has only elevated the group’s scientific reach. Together, IVI-RMA Global is the single-biggest investor in IVF research in the world.

genetic testing fertilty treatment

Published Research

Since its founding in 1999, RMA has published hundreds of pieces of research – including more than a dozen clinical trials – in an effort to improve patient outcomes.

Below is a non-exhaustive list of published works. To learn about IVI-RMA Global’s research, visit our Innovation website at ivi-rmainnovation.com.

2017
The Natural Cycle Study

Characterizing the natural menstrual cycle to determine embryonic aneuploidy. *Study showed that IVF without ovarian stimulation led to the same rate of abnormal embryos as stimulated IVF, but with less efficient outcomes. This showed women that their injectable medication was not causing an increase in the number of abnormal embryos.

ENMOTION (Embryo’s Natural Motion)

A paired randomized controlled trial demonstrating pregnancy rates are equivalent between static and dynamic culture systems. *Study showed that movement of embryos in culture (ie. micro-vibration), mimicking the natural process, had no impact on IVF outcomes.

ABC Trial: Appraisal of Body Content

Does body composition in couples undergoing IVF correlate with outcomes? Previous studies suggested inferior outcomes in obese patients undergoing IVF with fresh embryo transfers. This study demonstrated that with frozen embryo transfers, obese women have equivalent success rates to normal-weight counterparts when controlling for age. *This allowed patients to feel confident about success in IVF and subsequent pregnancy, regardless of body composition.

CAREs Trial

Celiac and reproductive effects – is the prevalence of celiac disease higher in the infertile population? Are IVF outcomes different in affected patients? *Study showed that seropositive celiac disease did not have an impact on patients’ IVF journey.

2016
neXgen

Next generation sequencing for embryo selection. *Study validated next generation genetic embryo testing platform. This allowed patients to know that the screening platform has undergone rigorous validation and is cutting edge in terms of technology.

Speak to a Fertility Specialist & Get Started

Submit the form for an appointment. For immediate new patient scheduling, call 866-762-3140.

Call to ScheduleRequest We Call You
Schedule Your First Visit866-762-3140

Existing patients with inquiries, please call your local office or send a message via the Artemis Patient Portal.